This inventor holds 2 USPTO granted patents. Top assignees: Taiho Pharmaceutical Company Limited, Maruko Seiyaku Co., Ltd., Seiyaku Co., Ltd.. Active years: 1983-1984.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Aza-nishimachi, JP (1983)
- Aichi, JP (1984)
Company Filing History:
2 out of 320 
1 out of 8 
1 out of 1 Years Active: 1983-1984
Title: Eiichi Katho: Innovator in Pharmaceutical Compounds
Introduction
Eiichi Katho is a notable inventor based in Aza-nishimachi, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on isoquinolone compounds. With a total of 2 patents, his inventions have the potential to impact various medical applications.
Latest Patents
Katho's latest patents focus on 1(2H)-isoquinolone compounds and their acid addition salts. These novel compounds are disclosed for their utility as pharmaceutical agents, showcasing activities such as anti-ulcer, stomach mucous membrane blood flow increasing, anti-hypertensive, analgesic, anti-histamine, anti-cholinergic, and gastric secretion inhibitory effects. The compounds are represented by a specific formula, where various groups and elements are defined to highlight their chemical structure and potential therapeutic benefits.
Career Highlights
Throughout his career, Eiichi Katho has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Taiho Pharmaceutical Company Limited and Maruko Seiyaku Co., Ltd. His work in these organizations has allowed him to develop and refine his innovative ideas in drug development.
Collaborations
Katho has collaborated with esteemed colleagues such as Shigeo Senda and Osamu Ohtani. These partnerships have likely contributed to the advancement of his research and the successful development of his patented compounds.
Conclusion
Eiichi Katho's contributions to the field of pharmaceuticals through his innovative isoquinolone compounds demonstrate his commitment to advancing medical science. His work has the potential to provide significant benefits in various therapeutic areas.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile